As gene therapy rivals advance, Biogen moves closer to spinning out hemophilia drugs, R&D
Lest anyone forget, Biogen is focused primarily on neuroscience. And it’s moving at a steady clip to spin off its hemophilia business in a tactic designed to underscore that strategy. Biogen today says the business will launch as Bioverativ in early 2017 and trade as $BIVV.
The business at Bioverativ will start by focusing on continuing to commercialize Eloctate and Alprolix, which were developed in partnership with Stockholm-based Sobi. And there’s a pipeline of new projects looking at expanding their use while adding new efforts on gene therapies and more for hemophilia A and B.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.